Journal
SCIENCE TRANSLATIONAL MEDICINE
Volume 6, Issue 222, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.3006804
Keywords
-
Categories
Funding
- Crown Princess Lovisas Foundation for Sick Children
- Vetenskapsradet grant [2011-6373]
- Hjart Lungfonden [20110500]
- Stockholms lans landsting (ALF) [2110471]
- Cancerfonden [100615]
- Vetenskapsradet [K2013-65X-21462-04-5]
- German Research Society [SFB 841 TP B8]
- European Research Council [ERC-StG-2012-311575_F-12]
Ask authors/readers for more resources
Currently used anticoagulants prevent thrombosis but increase bleeding. We show an anticoagulation therapy without bleeding risk based on a plasma protease factor XII function-neutralizing antibody. We screened for antibodies against activated factor XII (FXIIa) using phage display and demonstrated that recombinant fully human antibody 3F7 binds into the FXIIa enzymatic pocket. 3F7 interfered with FXIIa-mediated coagulation, abolished thrombus formation under flow, and blocked experimental thrombosis in mice and rabbits. We adapted an extracorporeal membrane oxygenation (ECMO) cardiopulmonary bypass system used for infant therapy to analyze clinical applicability of 3F7 in rabbits. 3F7 provided thromboprotection as efficiently as heparin, and both drugs prevented fibrin deposition and thrombosis within the extracorporeal circuit. Unlike heparin, 3F7 treatment did not impair the hemostatic capacity and did not increase bleeding from wounds. These data establish that targeting of FXIIa is a safe mode of thromboprotection in bypass systems, and provide a clinically relevant anticoagulation strategy that is not complicated by excess bleeding.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available